Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?

D A Cameron, A Anderson, E Toy, T R J Evans, J H Le Vay, I C S Kennedy, R J Grieve, T J Perren, A Jones, J Mansi, J Crown, R C F Leonard

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

After the publication of the 10-year survival data from Milan on the adjuvant use of the block sequential regimen consisting of four cycles of adriamycin followed by eight cycles of intravenous CMF, many centres adopted this as standard of care for high risk, multiple node-positive breast cancer. For this reason it was identified as the standard arm for the Anglo-Celtic adjuvant high-dose chemotherapy trial. This study reports on the experience of this regimen in 329 women with early breast cancer involving at least four axillary nodes, who were treated outside any adjuvant chemotherapy trial. At a median follow-up of 3 years, the overall 5-year disease-free survival is 61%, and the overall survival is 70%. These data confirm the efficacy of this regimen in non-trial patients, and, for the same high risk subgroup, indicate that this approach offers an outcome at least as good as that seen in the CALGB 9344 AC-Taxol arm, and the NCIC days 1 and 8 CEF.
Original languageEnglish
Pages (from-to)1365-9
Number of pages5
JournalBritish Journal of Cancer
Volume87
Issue number12
DOIs
Publication statusPublished - 2 Dec 2002

Keywords / Materials (for Non-textual outputs)

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Axilla
  • Breast Neoplasms
  • Cyclophosphamide
  • Disease-Free Survival
  • Doxorubicin
  • Female
  • Fluorouracil
  • Humans
  • Lymph Nodes
  • Lymphatic Metastasis
  • Methotrexate
  • Middle Aged
  • Risk Factors
  • Survival Rate
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?'. Together they form a unique fingerprint.

Cite this